Newsroom

TORONTO--(BUSINESS WIRE)--Roots (“Roots,” or the “Company”) (TSX: ROOT), a premium outdoor-lifestyle brand, announced today financial results for its first quarter ended May 2, 2026 (“Q1 2026”). All financial results are reported in Canadian dollars unless otherwise stated. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures. See “Non-IFRS Measures and Industry Metrics” below. Distribution Centre Transition Update In January 2026, the Company announced its str...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Rising Dividend Achievers UCITS ETF 11.06.2026 EDVY.LN IE000CPG9HG3 75,002.00 EUR 1,612,679.83 21.502  ...

NEWPORT NEWS, Va.--(BUSINESS WIRE)--  This is an initial notification of a transaction of a person discharging managerial responsibility (“PDMR”) in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). The Company announces that Robert Camposano, Senior Vice President, entered into a Rule 10b5-1 plan in respect of common stock of par value $0.0001 each in the Company (“Shares”) (ISIN US31488V1070) t...

NEWPORT NEWS, Va.--(BUSINESS WIRE)--This is an initial notification of a transaction of a person discharging managerial responsibility (“PDMR”) in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). The Company announces that Robert Camposano, Senior Vice President, entered into a Rule 10b5-1 plan in respect of common stock of par value $0.0001 each in the Company (“Shares”) (ISIN US31488V1070) tha...

DALLAS--(BUSINESS WIRE)--Invitation Homes Inc. (NYSE: INVH) (“Invitation Homes,” the “Company,” or “our”), the nation’s premier single-family home leasing and management company, announced today that it has declared a quarterly cash dividend of $0.30 per share payable on shares of its common stock. The dividend will be paid on or before July 17, 2026, to stockholders of record of the Company’s common stock as of the close of business on June 25, 2026. About Invitation Homes Invitation Homes, an...

MCLEAN, Va.--(BUSINESS WIRE)--Booz Allen will host a conference call at 8 a.m. EDT on Friday, July 24, 2026, to discuss financial results for the First Quarter of FY27....

ST. LOUIS--(BUSINESS WIRE)--Build-A-Bear Workshop, Inc. (NYSE: BBW) today announced that Chris Hurt has assumed the role of Chief Executive Officer (CEO), effective June 11, 2026. The transition follows the planned succession of Sharon Price John, who led the company for 13 years and will remain on the Board of Directors. Hurt, a seasoned executive with more than 11 years of leadership experience at Build-A-Bear, most recently served as Chief Operations and Experience Officer. During his tenure...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- BeOne Medicines Ltd.（Nasdaq：ONC、HKEX：06160、SSE：688235）は、グローバルなオンコロジー企業です。同社は、80歳以上の慢性リンパ性白血病または小リンパ球性リンパ腫（CLL/SLL）患者を対象とした大規模な第3相データセットを発表することを明らかにしました。このデータセットでは、約6.5年の追跡調査後もBRUKINSA®（ザヌブルチニブ）の持続的なベネフィットが示され、基盤となるBTK阻害薬としての同剤の役割が裏付けられました。BRUKINSAは、第3相試験でイブルチニブより優れた有効性を示した唯一のBTK阻害薬です1。未治療CLLの高齢患者に関する最大規模のデータセットの1つである本データセットは、スウェーデン・ストックホルムで開催される2026年欧州血液学会（EHA）総会で発表されます。 BeOneの血液領域チーフ・メディカル・オフィサー（CMO）であるアミット・アガルワル医学博士（M.D., Ph.D.）は、次のように述べています。 「CLL...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq : ONC ; HKEX : 06160 ; SSE : 688235), une société mondiale spécialisée en oncologie, a annoncé aujourd’hui la présentation d’un vaste ensemble de données de phase 3 chez des patients atteints de leucémie lymphoïde chronique ou de lymphome lymphocytaire de petite taille (LLC/SLL) âgés de 80 ans et plus, démontrant un bénéfice durable avec BRUKINSA après près de 6,5 ans de suivi, ce qui renforce son rôle d’inhibiteur de BTK de réfé...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布了一項針對80歲及以上慢性淋巴性白血病或小淋巴細胞淋巴瘤(CLL/SLL)病患的大型第三期資料集。資料顯示，在近6.5年的隨訪後，BRUKINSA仍能帶來持續獲益，進一步鞏固了其核心BTK抑制劑的地位。BRUKINSA是唯一在第三期試驗中顯示療效優於ibrutinib的BTK抑制劑。1這些資料是目前針對初治CLL老年病患的最大規模資料集之一，將在瑞典斯德哥爾摩舉行的2026年歐洲血液學協會(EHA)大會上公布。 BeOne Medicines血液學醫學長Amit Agarwal, M.D.博士表示： 「儘管CLL的診斷中位年齡為70歲，治療啟動的平均年齡為75歲，但許多關鍵試驗仍然未能充分代表醫生在臨床實務中最常遇到的病患群體。這些資料表明，BRUKINSA的持久獲益可以嘉惠80多歲的病患，包括那些具有高危特徵的病患。同樣重要的是，在臨床試驗和真實細節證據中，接受BRUKIN...